Differentiated Thyroid Cancer Treatment Market Report 2025 (Global Edition)

Global Differentiated Thyroid Cancer Treatment Market Report 2024 Market Size Split by Treatment type (Surgery, Total Thyroidectomy, Partial Thyroidectomy, Radioactive Iodine Therapy (RAI), Targeted T...

Differentiated Thyroid Cancer Treatment Market Report Description

We have various report editions of Differentiated Thyroid Cancer Treatment Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Differentiated Thyroid Cancer Treatment Market Insights Video

Competitive Landscape of the Differentiated Thyroid Cancer Treatment Market

The Competitive Landscape of the Differentiated Thyroid Cancer Treatment Market consists of multiple companies with wide ranges of competitiveness, all of which are now moving towards innovative therapies and treatment options. The existing players and new entrants will be based on a variety of approaches ranging from targeted therapies and radioactive iodine treatments to immunotherapies. If they are to be differentiated, the company must, of course, invest in ongoing research and development and an increasingly future the growing importance of industry collaborations where the increasing complexities of treatment mean that the best partnerships enhance rather than undermine the outcome for patients.

In November 2020, Exelixis Inc. revealed the positive findings of their clinical studies for cabozantinib, a targeted treatment for differentiated thyroid cancer. The favorable results sparked interest in the drug's potential for widespread use in thyroid cancer treatment. (Source: https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-encouraging-results-cabozantinib-combination) In February 2021, Curium SAS introduced a new radiopharmaceutical product intended exclusively for the diagnosis and treatment of differentiated thyroid cancer. This new technique is intended to improve patient outcomes and treatment accuracy. (Source:https://www.curiumpharma.com/2023/10/25/thyroid-imaging-partnership/ ) In February 2023, Pfizer Inc. gained permission for a new formulation of their existing thyroid cancer therapy, to improve patient compliance and outcomes. This research was part of their continuous effort to advance treatments for differentiated thyroid carcinoma. (Source: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-highlights-progress-accelerating-breakthrough-cancer)

Top Companies Market Share in Differentiated Thyroid Cancer Treatment Industry: (In no particular order of Rank)

• Jubilant Life Sciences (Jubilant DraxImage)
• Rosatom State Corporation (JSC Isotope)
• Curium SAS
• JEROME STEVENS PHARMACEUTICALS INC.
• Pfizer Inc.
• IBSA Group (IBSA Pharma Inc.)
• Mylan NV
• Sanofi (Genzyme Corporation)
• Exelixis Inc.
• Bayer AG
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Differentiated Thyroid Cancer Treatment Market

Which Region Dominates the Differentiated Thyroid Cancer Treatment Market in 2024?

According to Cognitive Market Research, North America dominates the differentiated thyroid cancer treatments market. This dominance is attributed to factors such as improved reimbursement regulations, developed healthcare facilities, and an increasing senior population

Which Region is Expanding at the Fastest CAGR?

The Asia Pacific market will increase rapidly in the next years as a result of pharmaceutical companies' developments, particularly in developing countries such as India and China, as well as the enormous pool of patients

The current report Scope analyzes Differentiated Thyroid Cancer Treatment Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Differentiated Thyroid Cancer Treatment

According to Cognitive Market Research, the global Differentiated Thyroid Cancer Treatment market size was estimated at USD 502.5 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 201.00 million in 2024 and will grow at a compound annual growth rate (CAGR) of 20.8% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Differentiated Thyroid Cancer Treatment market with a market size of USD 158.59 million in 2024 and is projected to grow at a CAGR of 20.6% during the forecast period. The U.S. market's advanced healthcare facilities and high levels of investment in cancer research
• The Canada Differentiated Thyroid Cancer Treatment market had a market share of USD 24.12 million in 2024 and is projected to grow at a CAGR of 21.6% during the forecast period. Canada’s rising demand for effective therapies.
• The Mexico Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 21.3% during the forecast period, with a market size of USD 18.29 million in 2024.

Europe Differentiated Thyroid Cancer Treatment

According to Cognitive Market Research, the global Differentiated Thyroid Cancer Treatment market size was estimated at USD 502.5 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 150.75 million in 2024 and will grow at a compound annual growth rate (CAGR) of 21.1% from 2024 to 2031.

• The United Kingdom Differentiated Thyroid Cancer Treatment market had a market share of USD 25.33 million in 2024 and is projected to grow at a CAGR of 21.9% during the forecast period. In the UK, Differentiated Thyroid Cancer Treatment sales witness an upswing due to the increasing awareness of thyroid cancer .
• The France Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 20.3% during the forecast period, with a market size of USD 13.87 million in 2024.
• According to Cognitive Market Research, the German Differentiated Thyroid Cancer Treatment market size was valued at USD 29.85 million in 2024 and is projected to grow at a CAGR of 21.3% during the forecast period. In Germany, Differentiated Thyroid Cancer Treatment surged due to the advancements in treatment options.
• The Italy Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 20.5% during the forecast period, with a market size of USD 12.96 million in 2024.
• The Russia Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 20.1% during the forecast period, with a market size of USD 23.37 million in 2024.
• The Spain Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 20.2% during the forecast period with a market size of USD 12.36 million in 2024
• The Luxembourg Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 21.2% during the forecast period, with a market size of USD 4.67 million in 2024.
• The Portugal Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 20.9% during the forecast period, with a market size of USD 3.17 million in 2024.
• The Greece Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 21.4% during the forecast period, with a market size of USD 1.69 million in 2024.
• The Rest of Europe's Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 19.8% during the forecast period, with a market size of USD 23.37 million in 2024.

Asia Pacific Differentiated Thyroid Cancer Treatment

According to Cognitive Market Research, the global Differentiated Thyroid Cancer Treatment market size was estimated at USD 502.5 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 115.58 million in 2024 and will grow at a compound annual growth rate (CAGR) of 24.6% from 2024 to 2031.

• According to Cognitive Market Research, the China Differentiated Thyroid Cancer Treatment market size was valued at USD 52.01 million in 2024 and is projected to grow at a CAGR of 24.1% during the forecast period. Differentiated Thyroid Cancer Treatment surged in China due to growing emphasis on personalized medicine .
• The Japan Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 23.1% during the forecast period, with a market size of USD 15.95 million in 2024.
• The India Differentiated Thyroid Cancer Treatment market had a market share of USD 13.87 million in 2024 and is projected to grow at a CAGR of 26.4% during the forecast period. India's rising government initiatives .
• The South Korean Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 23.7% during the forecast period, with a market size of USD 11.56 million in 2024.
• The Australian Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 24.3% during the forecast period, with a market size of USD 6.01 million in 2024.
• The South East Asia Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 25.6% during the forecast period, with a market size of USD 7.97 million in 2024.
• The Rest of Asia Pacific Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 24.4% during the forecast period, with a market size of USD 8.21 million in 2024.

South America Differentiated Thyroid Cancer Treatment

According to Cognitive Market Research, the global Differentiated Thyroid Cancer Treatment market size was estimated at USD 502.5 Million, out of which the Latin America held the market share of around 5% of the global revenue with a market size of USD 25.13 million in 2024 and will grow at a compound annual growth rate (CAGR) of 22.0% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Differentiated Thyroid Cancer Treatment market size was valued at USD 10.75 million in 2024 and is projected to grow at a CAGR of 22.6% during the forecast period. Differentiated Thyroid Cancer Treatments flourished in Brazil due to rising awareness about the disease.
• Argentina's Differentiated Thyroid Cancer Treatment market had a market share of USD 4.22 million in 2024 and is projected to grow at a CAGR of 22.9% during the forecast period. Argentina's rising personal disposable income .
• Colombia Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 21.8% during the forecast period, with a market size of USD 2.24 million in 2024.
• Peru Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 22.2% during the forecast period, with a market size of USD 2.06 million in 2024.
• Chile Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 22.3% during the forecast period, with a market size of USD 1.81 million in 2024.
• The Rest of Latin America's Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 21.1% during the forecast period, with a market size of USD 4.05 million in 2024.

Middle East and Africa Differentiated Thyroid Cancer Treatment

According to Cognitive Market Research, the global Differentiated Thyroid Cancer Treatment market size was estimated at USD 502.5 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 10.05 million in 2024 and will grow at a compound annual growth rate (CAGR) of 22.3% from 2024 to 2031..

• The GCC Countries Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 23.1% during the forecast period, with a market size of USD 4.30 million in 2024. Differentiated Thyroid Cancer Treatment sales flourish due to the presence of major market players.
• The Egypt Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 22.6% during the forecast period, with a market size of USD 1.06 million in 2024.
• The South Africa Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 23.3% during the forecast period, with a market size of USD 1.59 million in 2024. Differentiated Thyroid Cancer Treatment sales flourished in South Africa due to advancements in medical technology.
• The Turkey Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 21.8% during the forecast period, with a market size of USD 0.86 million in 2024.
• The Nigeria Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 21.4% during the forecast period, with a market size of USD 1.06 million in 2024.
• The Rest of the MEA Differentiated Thyroid Cancer Treatment market is projected to witness growth at a CAGR of 21.3% during the forecast period, with a market size of USD 1.19 million in 2024.

Differentiated Thyroid Cancer Treatment Market Analysis

Differentiated Thyroid Cancer Treatment Market Treatment Type Segment Analysis

According to Cognitive Market Research, Over the projected period, the chemotherapy sector will account for a considerable portion of the DTC therapies market. The dominance is due to the widespread use of medications such as doxorubicin, cisplatin, and others as conventional treatments. The usage of combination medications, as well as their proven efficacy in preventing cancer progression, has resulted in high demand. These combination medications slow the progression of drug resistance, which is projected to drive the market

Targeted therapy is expected to have the highest CAGR. The lucrative growth is attributable to their use as cancer progresses. Furthermore, these targeted medications have distinct effects on thyroid cancer than traditional chemotherapy drugs. These drugs prevent tumors from generating new blood vessels and target certain proteins that promote cancer cell proliferation. The lower side effects compared to chemotherapy are projected to drive segment growth

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Differentiated Thyroid Cancer Treatment Industry. Request a Free Sample PDF!

Differentiated Thyroid Cancer Treatment Market Drug Class Segment Analysis

According to Cognitive Market Research, Tyrosine Kinase Inhibitors have the largest share in the Differentiated Thyroid Cancer Treatment Market. These TKIs, lenvatinib, or sorafenib proved to inhibit the growth and proliferation of cancer cells, especially when traditional therapy fails and the patient is in stage III or IV of thyroid carcinoma.

Another fast-emerging segment is Monoclonal Antibodies. These targeted therapies are finding wide acceptance because they selectively kill the cancer cells and aid in their deaths. The number of clinical trials and studies being carried out on monoclonal antibodies is on the rise. Therefore, Tyrosine Kinase Inhibitors and Monoclonal Antibodies are two of the most prominent categories in the Differentiated Thyroid Cancer Treatment Market.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Differentiated Thyroid Cancer Treatment Stage Segment Analysis

Differentiated Thyroid Cancer Treatment Market Stage Segment Analysis

According to Cognitive Market Research, Stage I is the most common segment of the Differentiated Thyroid Cancer Treatment Market. It is considered so because the majority of the cancers in this stage were diagnosed at an early stage, and treatment would then be potent enough to provide a very good chance of survival. Patients normally respond very well to first-line therapies, such as surgery and radioactive iodine treatment.

Stage IV is the growth rate segment with the highest growth rate. Stage IV thyroid cancer indicates advanced disease with metastasis where treatment approaches would need to be sophisticated and innovative like Tyrosine Kinase Inhibitors and Monoclonal Antibodies. The requirement of such complex therapies for patients diagnosed with stage IV cancer and also introduction of certain new products designed only for such patients are other driving factors contributing to this market at a high growth rate.

• Stage I
• Stage II
• Stage III
• Stage IV

Differentiated Thyroid Cancer Treatment Route of administration Segment Analysis

Differentiated Thyroid Cancer Treatment Market Route of Administration Segment Analysis

According to Cognitive Market Research, the Oral segment comprises the greatest share of the Differentiated Thyroid Cancer Treatment Market. The majority of Tyrosine Kinase Inhibitors, like lenvatinib and sorafenib, are presented in oral forms. This route is cost-effective and less stressful for the patient as it can be administered at home

The Intravenous segment is a fast-growing segment. Although it currently takes up a lower share of the market as compared with the oral segment, new emerging therapies and higher usage rates of intravenous monoclonal antibodies are also driving growth. Intravenous treatments may work better for patients suffering from more advanced cancers, which increases demand rates for such kinds of treatments.

• Oral
• Intravenous
• Others

Differentiated Thyroid Cancer Treatment Distribution Channel Segment Analysis

Differentiated Thyroid Cancer Distribution Channel Market Stage Segment Analysis

According to Cognitive Market Research, Hospitals Pharmacy Leads the way in Differentiated Thyroid Cancer Treatment Market primarily because several cancer treatments are sold through hospitals, especially specialized handling or administration- therapies administered intravenously. Hospital pharmacies offer a variety of cancer treatments and there are healthcare professionals who can help patients with a particular need.

Online pharmacies are growing at the fastest rate. As there is a trend towards digital health solutions, and it is convenient to buy medications online, the growth rate for online pharmacies is observed to be the highest. Patients appreciated the ability to order prescriptions from home, and the rise in telemedicine has further favored online pharmacies.

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion